OptimizeRx OPRX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $23.37M+74.6% | $13.38M-3.4% | $13.85M-23.9% | $18.21M-78.5% | ||
| $8.66M+4.3% | $8.3M— | —— | $55.93M— | ||
| $37.75M-1.2% | $38.21M+1,062% | $3.29M-8.2% | $3.58M+69.7% | ||
| $64.72M+19.9% | $53.97M-0.7% | $54.33M-44.9% | $98.58M-14.4% | ||
| $106K-29.3% | $150K+0.7% | $149K+8.4% | $137.45K-4.4% | ||
| $70.87M0.0% | $70.87M-9.6% | $78.36M+246% | $22.67M+53.8% | ||
| $40.8M+639% | $5.52M-10.8% | $6.19M+83.0% | $3.38M-13.4% | ||
| $176.92M+3.4% | $171.17M-6.7% | $183.37M+36.2% | $134.65M-4.5% | ||
| $1.64M-24.1% | $2.16M-3.2% | $2.23M+43.7% | $1.55M+155% | ||
| $503K+6.3% | $473K+175% | $171.84K+4.6% | $164.31K-88.2% | ||
| $4.26M+113% | $2M0.0% | $2M— | —— | ||
| $21.26M+14.0% | $18.65M+4.3% | $17.88M+113% | $8.4M-10.4% | ||
| $21.42M-30.5% | $30.82M-10.0% | $34.23M— | —— | ||
| $48.62M-10.2% | $54.17M-4.7% | $56.82M+565% | $8.54M-11.1% | ||
| 166.7M+833,233% | 20K-100.0% | 166.7M0.0% | 166.7M0.0% | ||
| -$79.24M+6.1% | -$84.37M-31.3% | -$64.26M-37.6% | -$46.69M-32.4% | ||
| $128.29M+9.7% | $117M-7.6% | $126.55M+0.4% | $126.11M-4.0% | ||
| $176.92M+3.4% | $171.17M-6.7% | $183.37M+36.2% | $134.65M-4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are OptimizeRx's total assets?
- OptimizeRx (OPRX) holds $167.3M in total assets, down 0.3% year over year.
- How much debt does OptimizeRx have?
- OptimizeRx carries $23.7M in total debt against $129.6M of shareholders' equity, a debt-to-equity ratio of 0.18.
- How much cash does OptimizeRx have?
- OptimizeRx holds $20.2M in cash and equivalents.
- Can OptimizeRx cover its short-term obligations?
- Its current ratio is 5.37 — current assets exceed current liabilities.
- Where does OptimizeRx's balance sheet data come from?
- Every line is extracted from OptimizeRx's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
